The University of Texas MD Anderson Cancer Center has received a USD 1.82 million National Cancer Institute R01 renewal to investigate how the transcription factor Bhlhe40 governs T cell effector function during immune checkpoint therapy (ICT) and neoantigen cancer vaccines — research that could identify a novel target for improving response rates in patients who fail current immunotherapies.
Preclinical data from the lab of principal investigator Matthew M. Gubin demonstrated that anti-PD-1 and anti-CTLA-4 treatment strongly upregulates Bhlhe40 in tumor antigen-specific CD4 and CD8 T cells in sarcoma and melanoma models. Conditional deletion of Bhlhe40 rendered mice unable to reject ICT-sensitive tumors, with Bhlhe40-deficient T cells showing reduced interferon-gamma production and impaired remodeling of intratumoral macrophages. The renewed grant will use T cell-specific knockout models, single-cell RNA sequencing, scATAC-seq, ChIP-seq, and CODEX multiplex imaging to dissect how Bhlhe40 controls chromatin accessibility and transcriptional programs in both CD4 and CD8 compartments — a distinction the earlier work did not fully resolve. A third aim will translate findings to human samples by manipulating Bhlhe40 expression in human T cells and analyzing pre- and post-treatment patient material.
The focus on CD4 T cells alongside CD8 cells reflects a broader shift in the immuno-oncology field, where helper T cell contributions to durable tumor rejection are increasingly recognized as essential rather than ancillary. Bhlhe40 has no current clinical-stage inhibitors or activators, positioning it as an early-stage but mechanistically grounded target. Competing approaches to T cell dysfunction — including next-generation checkpoint combinations, TIL therapies, and transcription factor-focused programs targeting TOX or NR4A — underscore both the opportunity and the crowded landscape for improving ICT response.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Spot something wrong? Report an issue with this article